RGNX
Price
$8.96
Change
-$0.17 (-1.86%)
Updated
Jul 25 closing price
Capitalization
451.48M
3 days until earnings call
VRTX
Price
$469.65
Change
-$2.62 (-0.55%)
Updated
Jul 25 closing price
Capitalization
120.6B
8 days until earnings call
Interact to see
Advertisement

RGNX vs VRTX

Header iconRGNX vs VRTX Comparison
Open Charts RGNX vs VRTXBanner chart's image
REGENXBIO
Price$8.96
Change-$0.17 (-1.86%)
Volume$467.43K
Capitalization451.48M
Vertex Pharmaceuticals
Price$469.65
Change-$2.62 (-0.55%)
Volume$1.18M
Capitalization120.6B
RGNX vs VRTX Comparison Chart in %
Loading...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
RGNX vs. VRTX commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RGNX is a Hold and VRTX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (RGNX: $8.96 vs. VRTX: $472.27)
Brand notoriety: RGNX and VRTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RGNX: 54% vs. VRTX: 0%
Market capitalization -- RGNX: $451.48M vs. VRTX: $120.6B
RGNX [@Biotechnology] is valued at $451.48M. VRTX’s [@Biotechnology] market capitalization is $120.6B. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RGNX’s FA Score shows that 1 FA rating(s) are green whileVRTX’s FA Score has 2 green FA rating(s).

  • RGNX’s FA Score: 1 green, 4 red.
  • VRTX’s FA Score: 2 green, 3 red.
According to our system of comparison, VRTX is a better buy in the long-term than RGNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RGNX’s TA Score shows that 4 TA indicator(s) are bullish while VRTX’s TA Score has 7 bullish TA indicator(s).

  • RGNX’s TA Score: 4 bullish, 6 bearish.
  • VRTX’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, VRTX is a better buy in the short-term than RGNX.

Price Growth

RGNX (@Biotechnology) experienced а +9.80% price change this week, while VRTX (@Biotechnology) price change was +2.71% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.62%. For the same industry, the average monthly price growth was +17.39%, and the average quarterly price growth was +28.36%.

Reported Earning Dates

RGNX is expected to report earnings on Nov 05, 2025.

VRTX is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Biotechnology (+7.62% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRTX($121B) has a higher market cap than RGNX($451M). VRTX YTD gains are higher at: 17.276 vs. RGNX (15.912). VRTX has higher annual earnings (EBITDA): -74.9M vs. RGNX (-122.44M). VRTX has more cash in the bank: 6.2B vs. RGNX (268M). RGNX has less debt than VRTX: RGNX (79.8M) vs VRTX (1.65B). VRTX has higher revenues than RGNX: VRTX (11.1B) vs RGNX (157M).
RGNXVRTXRGNX / VRTX
Capitalization451M121B0%
EBITDA-122.44M-74.9M163%
Gain YTD15.91217.27692%
P/E RatioN/A32.76-
Revenue157M11.1B1%
Total Cash268M6.2B4%
Total Debt79.8M1.65B5%
FUNDAMENTALS RATINGS
RGNX vs VRTX: Fundamental Ratings
RGNX
VRTX
OUTLOOK RATING
1..100
1763
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
77
Overvalued
PROFIT vs RISK RATING
1..100
10029
SMR RATING
1..100
9691
PRICE GROWTH RATING
1..100
5956
P/E GROWTH RATING
1..100
2333
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

RGNX's Valuation (72) in the Biotechnology industry is in the same range as VRTX (77). This means that RGNX’s stock grew similarly to VRTX’s over the last 12 months.

VRTX's Profit vs Risk Rating (29) in the Biotechnology industry is significantly better than the same rating for RGNX (100). This means that VRTX’s stock grew significantly faster than RGNX’s over the last 12 months.

VRTX's SMR Rating (91) in the Biotechnology industry is in the same range as RGNX (96). This means that VRTX’s stock grew similarly to RGNX’s over the last 12 months.

VRTX's Price Growth Rating (56) in the Biotechnology industry is in the same range as RGNX (59). This means that VRTX’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's P/E Growth Rating (23) in the Biotechnology industry is in the same range as VRTX (33). This means that RGNX’s stock grew similarly to VRTX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RGNXVRTX
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
53%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
62%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
66%
MACD
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
55%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
58%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
63%
Advances
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 4 days ago
59%
Declines
ODDS (%)
Bearish Trend 16 days ago
84%
Bearish Trend 2 days ago
42%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
59%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
61%
View a ticker or compare two or three
Interact to see
Advertisement
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MSEGX60.410.55
+0.92%
Morgan Stanley Inst Growth A
NNLEX25.560.16
+0.63%
Nicholas Limited Edition N
KLCAX18.280.11
+0.61%
Federated Hermes Kaufmann Large Cap A
PMYRX12.890.02
+0.16%
Victory Pioneer Equ Premium Income Y
CBWTF0.11N/A
-3.59%
Auxly Cannabis Group Inc.